Citadel Advisors’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Citadel Advisors’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-869	Closed	-$40.4K	–	15548
2023 Q2	$40.4K	Sell	869 -201,223	-100%	-$6.95M	﹤0.01%	12052
2023 Q1	$5.79M	Buy	202,092 +52,537	+35%	+$1.56M	﹤0.01%	3564
2022 Q4	$4.67M	Sell	149,555 -455,611	-75%	-$14.9M	﹤0.01%	3970
2022 Q3	$12.3M	Sell	605,166 -318,683	-34%	-$5.81M	﹤0.01%	2463
2022 Q2	$14.3M	Buy	923,849 +809,864	+711%	+$13.9M	﹤0.01%	2231
2022 Q1	$2.18M	Buy	113,985 +4,629	+4%	+$82.6K	﹤0.01%	5901
2021 Q4	$2.77M	Buy	+109,356	New	+$3.2M	﹤0.01%	5491

Citadel Advisors's DICE Position: Q3 2023 in Review

Citadel Advisors sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 869 shares — an estimated $40.4K sold.

Citadel Advisors first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $14.3M in Q2 2022. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Citadel Advisors reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Citadel Advisors sold 869 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $40.4K.
Citadel Advisors first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Citadel Advisors's DICE Therapeutics, Inc. Common Stock position peaked at $14.3M in Q2 2022.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.